Human JAK3 deficiencies and inactivating mutations also result in SCID.21–24 The fact that therapeutic blockade of JAK3 is achievable without life-threatening toxicity relates back to the reversible and/or transient enzymatic blockade intrinsic to small molecule drugs versus the permanent absence with genetic deficiencies. Here, JAK3 is linked to severe combined immunodeficiency.